Peter A Kuhn

US Patent:

8252899, Aug 28, 2012

Filed:

Oct 22, 2008

Appl. No.:

12/739134

Inventors:

Raymond C. Stevens - La Jolla CA, US
Michael A. Hanson - San Marcos CA, US
Vadim Cherezov - San Diego CA, US
Peter Kuhn - Solana Beach CA, US

Assignee:

The Scripps Research Institute - La Jolla CA

International Classification:

C07K 1/00
C07K 14/00
C12N 9/00

US Classification:

530350, 530419, 435183

Abstract:

The invention describes compositions and method useful for the crystallization of membrane proteins.

US Patent:

8445225, May 21, 2013

Filed:

Sep 3, 2009

Appl. No.:

12/553733

Inventors:

Peter Kuhn - Solana Beach CA, US
John Ho Griffin - Del Mar CA, US
Kelly Bethel - San Diego CA, US
Dena Marrinucci - Del Mar CA, US

Assignee:

The Scripps Research Institute - La Jolla CA

International Classification:

C12Q 1/02
C12Q 1/68
G01N 33/53

US Classification:

435 29, 435 614, 435 72

Abstract:

The present invention provides methods for revealing, detecting, and analyzing circulating tumor cells in the blood of a subject. Revealing detectable circulating tumor cells allows for early stage detection and diagnosis in addition to long term prognosis in subjects with cancer. Additionally, enrichment allows for robust detection and clinically meaningful analysis of low volume samples for use in clinical settings as well as innovative methods for the treatment of cancers.

US Patent:

20070050152, Mar 1, 2007

Filed:

Aug 24, 2006

Appl. No.:

11/510422

Inventors:

Raymond Stevens - La Jolla CA, US
Peter Kuhn - Solana Beach CA, US
Maneesh Yadav - San Diego CA, US

International Classification:

G06F 19/00

US Classification:

702019000

Abstract:

A method is provided for acquiring X-ray diffraction images of a protein crystal, the method comprising providing an X-ray source and a micro-channel, wherein the micro-channel contains an oil, gas or immiscible liquid and at least one aqueous droplet comprising a crystal of a protein, recording an X-ray diffraction image of the crystal, repositioning the crystal with respect to the X-ray source, and repeating the last two steps immediately above at least once.

US Patent:

20080020984, Jan 24, 2008

Filed:

Jul 23, 2007

Appl. No.:

11/781738

Inventors:

Peter Kuhn - Solana Beach CA, US
Anand Kolatkar - San Diego CA, US
Alexei Brooun - San Diego CA, US
Jill Chrencik - San Diego CA, US
Michelle Kraus - Temecula CA, US

Assignee:

The Scripps Research Institute - La Jolla CA

International Classification:

G06G 7/48
A61K 38/00
C07K 1/00
C07K 14/00
C40B 30/04
G01N 33/00

US Classification:

514013000, 436086000, 506009000, 530325000, 530345000, 703011000

Abstract:

The invention relates to the three-dimensional structure of a crystal of an EphB4 receptor complexed with a ligand. The three-dimensional structure of a Receptor-Ligand Complex is disclosed. The receptor-ligand crystal structure, wherein the ligand is an inhibitor molecule, is useful for providing structural information that may be integrated into drug screening and drug design processes. Thus, the invention also relates to methods for utilizing the crystal structure of the Receptor-Ligand Complex for identifying, designing, selecting, or testing inhibitors of the EphB4 receptor protein, such inhibitors being useful as therapeutics for the treatment or modulation of i) diseases; ii) disease symptoms; or iii) the effect of other physiological events mediated by the receptor.

US Patent:

20080064052, Mar 13, 2008

Filed:

Jan 12, 2007

Appl. No.:

11/622785

Inventors:

Peter Kuhn - Solana Beach CA, US
Alexei Brooun - San Diego CA, US
Jill Chrencik - San Diego CA, US
Michelle Kraus - Temecula CA, US

Assignee:

The Scripps Research Institute - La Jolla CA

International Classification:

G01N 33/00
C07K 1/00
G06G 7/48

US Classification:

435007920, 530350000, 703011000

Abstract:

The invention relates to the three-dimensional structure of a crystal of an EphB4 receptor complexed with a ligand. The three-dimensional structure of a Receptor-Ligand Complex is disclosed. The receptor-ligand crystal structure, wherein the ligand is an inhibitor molecule, is useful for providing structural information that may be integrated into drug screening and drug design processes. Thus, the invention also relates to methods for utilizing the crystal structure of the Receptor-Ligand Complex for identifying, designing, selecting, or testing inhibitors of the EphB4 receptor protein, such inhibitors being useful as therapeutics for the treatment or modulation of i) diseases; ii) disease symptoms; or iii) the effect of other physiological events mediated by the receptor.

US Patent:

20090317836, Dec 24, 2009

Filed:

Jan 30, 2007

Appl. No.:

12/223351

Inventors:

Peter Kuhn - Solana Beach CA, US
Dena Marrinucci - Solana Beach CA, US

Assignee:

The Scripps Research Institute - La Jolla CA

International Classification:

G01N 33/574

US Classification:

435 723

Abstract:

Methods are provided for detecting circulating tumor cells in a mammalian subject. Methods of diagnosing cancer in a mammalian subject are provided. The methods of detection or diagnosis indicate the presence of metastatic cancer or early stage cancer.

US Patent:

20120100593, Apr 26, 2012

Filed:

Sep 2, 2011

Appl. No.:

13/199611

Inventors:

Raymond C. Stevens - La Jolla CA, US
Michael A. Hanson - San Marcos CA, US
Vadim Cherezov - San Diego CA, US
Peter Kuhn - Solana Beach CA, US

Assignee:

The Scripps Research Institute - La Jolla CA

International Classification:

C12N 9/96

US Classification:

435188

Abstract:

A polypeptide in crystalline form comprises a G-protein coupled receptor (GPCR) with an IC3 loop substituted by an amino acid residue sequence of lysozyme.

US Patent:

20120178094, Jul 12, 2012

Filed:

Sep 2, 2010

Appl. No.:

13/393177

Inventors:

Peter Kuhn - Solana Beach CA, US

International Classification:

C12Q 1/68
G01N 33/574

US Classification:

435 612, 435 723

Abstract:

The present invention provides method for categorizing circulating tumor cells (CTCs) using various cellular markers and revealing or non-revealing assays which provide beneficial insights for clinical staging and therapy decision making in cancer patients.